GlassScriptPhysician profile
Garrick D Brown
NPI 1407829047
$3,653.63
in general payments reported to CMS, 2019-2025
27 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2022: $184 · 2023: $479 · 2024: $1,363 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,139 · Education: $50.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,139.07 |
| Education | $50.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,031.28 | 2019-2025 | Skyrizi, Viberzi, Linzess |
| Pfizer INC. | $384.21 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $355.10 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $340.20 | 2023-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $289.48 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Ipsen Biopharmaceuticals, INC | $163.22 | 2024-2025 | Iqirvo, Bylvay |
| Janssen Scientific Affairs, LLC | $154.74 | 2024-2025 | |
| Genzyme Corporation | $149.15 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $123.09 | 2022 | |
| Aimmune Therapeutics, INC. | $122.76 | 2025 | Zenpep, Vowst |
| Celltrion USA INC. | $75.89 | 2024-2025 | Zymfentra, Vegzelma |
| Janssen Biotech, INC. | $71.10 | 2024-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $53.31 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $47.96 | 2024 | Dificid |
| Lilly USA, LLC | $46.03 | 2024 | Omvoh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $31.37 | 2023-2025 | Renflexis, Hadlima |
| Gilead Sciences, INC. | $30.24 | 2025 | |
| Qol Medical, LLC | $28.06 | 2025 | Sucraid |
| Braintree Laboratories, INC. | $24.61 | 2022 | |
| Exact Sciences Corporation | $23.39 | 2023 | Cologuard Collection Kit |
| Intuitive Surgical, INC. | $21.62 | 2025 | |
| Novo Nordisk INC | $18.95 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $17.82 | 2023 | |
| Intercept Pharmaceuticals, INC. | $17.26 | 2024 | |
| Allergan, INC. | $16.87 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $15.92 | 2023 | Lockado |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,464.18 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrick Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.